Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 25 | SFEBES2011 | Next issue

Society for Endocrinology BES 2011


Novel pathways and treatments in neuroendocrine tumours

ea0025s2.1 | Novel pathways and treatments in neuroendocrine tumours | SFEBES2011

Signaling pathways in neuroendocrine tumors

Kidd Mark , Modlin I

Neuroendocrine tumor cells express a diverse array of activating and inhibitory receptors. Each receptor transduces a signal via individual pathways which often interact or overlap. Common stimulatory receptor families include those for EGF/TGFα, FGF, IGF, PDGF, VEGF, and TGFβ. EGF receptor (Her 1) activation results in several signal transduction cascades including Ras/Raf, MAPK, AKT and JNK leading to DNA synthesis and cell proliferation. Activated MAPK signaling i...

ea0025s2.2 | Novel pathways and treatments in neuroendocrine tumours | SFEBES2011

Integrated genome-wide DNA methylation and mRNA expression analysis of pancreatic NETs

Thirlwell Christina , Schulz Laura , Eymard Marianne , Meyer Tim , Davidson Brian , Teschendorff Andrew , Jiao Yan , Luong Tu-Vinh , Caplin Martyn , Beck Stephan

Integration of genetics and epigenetics has emerged as a powerful approach to study cellular differentiation and tumourigenesis. The study of DNA methylation is of particular importance in cancer as causal involvement has been demonstrated and it is the most stable of all epigenetic modifications, making it a desirable marker for both early detection and treatment of tumours. Hypermethylation of CpG sites in gene promoter regions leads to decreased gene expression, if such a g...

ea0025s2.3 | Novel pathways and treatments in neuroendocrine tumours | SFEBES2011

Tyrosine kinase inhibitors for neuroendocrine tumours

Valle Juan W

Neuroendocrine tumours (NETs) are a heterogeneous, uncommon tumours for whom there have been few practice-changing clinical studies. Sub-groups of patients may be defined by site of origin, histological sub-type, mitotic activity and evidence of disease progression.Chemotherapy is active in patients with advanced pancreatic NETs; however, benefits are modest and associated with significant (albeit manageable) toxicity. Additional treatment options are sp...